Ignite Creation Date:
2024-05-05 @ 9:28 PM
Last Modification Date:
2024-10-26 @ 10:05 AM
Study NCT ID:
NCT00897455
Status:
UNKNOWN
Last Update Posted:
2011-03-23
First Post:
2009-05-09
Brief Title:
Studying Breast Cancer Risk in Women Who Are BRCA1BRCA2 Mutation Carriers
Sponsor:
Gynecologic Oncology Group
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Genetic Modifiers of BRCA1BRCA2-Related Breast Cancer Risk in BRCA1BRCA2 Mutation Carriers - CIMBA 5
Status:
UNKNOWN
Status Verified Date:
2011-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Studying samples of DNA in the laboratory from women who are BRCA1BRCA2 mutation carriers may help doctors learn more about cancer and identify biomarkers related to cancer
PURPOSE This research study is looking at breast cancer risk in women who are BRCA1BRCA2 mutation carriers
PURPOSE This research study is looking at breast cancer risk in women who are BRCA1BRCA2 mutation carriers
Detailed Description:
OBJECTIVES
To identify potential genetic modifiers of breast cancer risk by contributing data and genetic information obtained from women who are BRCA1BRCA2 mutation carriers enrolled in clinical trial GOG-0199 to an international consortium of clinical cancer genetics investigators CIMBA
OUTLINE This is a multicenter study Patients are stratified by study country of residence ethnicity and birth cohort Joint analyses of BRCA1 and BRCA2 mutation carriers are further stratified by mutation
Previously collected DNA samples are analyzed for genetic variants in selected candidate genes rs16942 in BRCA1 rs2237060 in RAD50 SNP3 and rs2241193 in IGFBP5 The single nucleotide polymorphism SNP data from this study and selected demographic clinical and epidemiological data obtained from the baseline questionnaire administered in the GOG-0199 study are submitted to the Consortium of Investigators of Modifiers of BRCA-Associated Cancer CIMBA Central Database The epidemiological and SNP data contributed to the Central Database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway
To identify potential genetic modifiers of breast cancer risk by contributing data and genetic information obtained from women who are BRCA1BRCA2 mutation carriers enrolled in clinical trial GOG-0199 to an international consortium of clinical cancer genetics investigators CIMBA
OUTLINE This is a multicenter study Patients are stratified by study country of residence ethnicity and birth cohort Joint analyses of BRCA1 and BRCA2 mutation carriers are further stratified by mutation
Previously collected DNA samples are analyzed for genetic variants in selected candidate genes rs16942 in BRCA1 rs2237060 in RAD50 SNP3 and rs2241193 in IGFBP5 The single nucleotide polymorphism SNP data from this study and selected demographic clinical and epidemiological data obtained from the baseline questionnaire administered in the GOG-0199 study are submitted to the Consortium of Investigators of Modifiers of BRCA-Associated Cancer CIMBA Central Database The epidemiological and SNP data contributed to the Central Database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOG-8008 | None | None | None |